A Study of LY2541546 in Women With Low Bone Mineral Density
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study include evaluating the dose response of LY2541546 using
bone mineral density (BMD) change from baseline as compared to placebo and evaluating the
overall safety and tolerability of LY2541546 following multiple subcutaneous administrations
in postmenopausal (PMP) women with low BMD. Following the last dose of study drug,
participants will be able to participate in a 12 month extension to collect additional safety
and efficacy data (no further treatment will be administered during this extension).